全身炎症标志物对晚期上皮性卵巢癌新辅助铂类反应及铂耐药的预后价值:基于腹膜癌指数的分析
本研究评估治疗前全身炎症指标对晚期卵巢癌患者铂类新辅助化疗反应的预测价值,以腹膜癌指数(PCI)下降率衡量反应,并评估其预测铂耐药的能力。结果显示治疗前炎症标志物与PCI下降率呈显著正相关,SII预测铂耐药的曲线下面积(AUC)为0.790,NLR>11.43和SII>2223.15为预测耐药的最佳截断值。
要点
- 治疗前全身炎症标志物与PCI下降率呈显著正相关,SII较高者化疗反应更强。
- SII预测铂耐药的AUC为0.790,诊断准确性最高。
- NLR>11.43和SII>2223.15为预测铂耐药的最佳截断值,敏感性和特异性良好。
核心结论
- 全身炎症指标尤其是SII似乎是晚期卵巢癌有价值的预测和预后生物标志物。
- 治疗前评估中使用这些指标可能有助于识别化疗反应差风险的患者并指导个体化治疗策略,包括可能需要贝伐珠单抗等联合治疗。
研究设计与样本
- 研究对象为接受新辅助化疗后行间歇性肿瘤细胞减灭术的FIGO IIIc-IV期上皮性卵巢癌患者。
- 治疗前记录中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、单核细胞与淋巴细胞比值(MLR)和全身免疫炎症指数(SII)。
- 分析这些标志物与治疗后PCI下降率的相关性,并用受试者工作特征(ROC)曲线分析评估其对铂耐药的预测能力。
主要发现
- 治疗前全身炎症标志物与PCI下降率呈统计学显著正相关。
- 基线值较高尤其SII较高与更大的PCI下降相关,表明对化疗反应更强。
- SII预测铂耐药的诊断准确性最高,AUC为0.790。
- NLR>11.43和SII>2223.15为预测耐药的最佳截断值,敏感性和特异性良好。
关键数值与推荐
- NLR最佳截断值>11.43。
- SII最佳截断值>2223.15。
- SII预测铂耐药的AUC为0.790。
临床怎么用
- 作者认为全身炎症指标尤其是SII似乎是有价值的预测和预后生物标志物。
- 作者认为治疗前评估中使用这些指标可能有助于识别化疗反应差风险的患者并指导个体化治疗策略,包括可能需要贝伐珠单抗等联合治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the prognostic value of pre-treatment systemic inflammatory indices in predicting the response to platinum-based neoadjuvant chemotherapy in patients with advanced ovarian cancer (AOC), as measured by the reduction rate of the Peritoneal Cancer Index (PCI). Additionally, the study sought to assess the predictive power of these markers in identifying patients likely to develop platinum resistance. METHODS: Systemic inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) and systemic immune-inflammation index (SII) were recorded prior to treatment in patients diagnosed with FIGO stage IIIc-IV epithelial ovarian cancer who received neoadjuvant chemotherapy followed by interval debulking surgery. Correlations between these markers and post-treatment PCI reduction rates were analyzed. The predictive ability of these markers for platinum resistance was evaluated using receiver operating characteristic (ROC) curve analysis. RESULTS: Pre-treatment systemic inflammatory markers showed a statistically significant positive correlation with PCI reduction rate. Higher baseline values, particularly of SII, were associated with a greater PCI reduction, indicating a stronger response to chemotherapy. SII demonstrated the highest diagnostic accuracy for predicting platinum resistance, with an area under the curve (AUC) of 0.790. Optimal cut-off values for NLR (>11.43) and SII (>2223.15) were identified, showing good sensitivity and specificity for predicting resistance. CONCLUSION: Systemic inflammatory indices, especially SII, appear to be valuable predictive and prognostic biomarkers in AOC. Their use in pre-treatment evaluation may help identify patients at risk of poor chemotherapy response and guide personalized treatment strategies, including the potential need for combination therapies such as bevacizumab.
引用
- Bektaş O, Bektaş K. Prognostic value of systemic inflammatory markers in predicting neoadjuvant platinum response and platinum resistance in advanced epithelial ovarian cancer: A peritoneal cancer index-based analysis. Gynecol Oncol. 2025. PMID: 40639064. doi:10.1016/j.ygyno.2025.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。